Skip to content
Baltimore News Journal – Lifestyle
Author:
Boehringer Ingelheim Limited
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
April 15, 2026
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
April 13, 2026
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
April 9, 2026
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
April 9, 2026
Boehringer Ingelheim’s Athens Site Achieves Carbon Neutral Operations, Advancing 2030 Commitments
April 6, 2026
←
Previous Page
1
2
3